Trial Profile
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ularitide (Primary)
- Indications Acute heart failure; Decompensated heart failure
- Focus Registrational; Therapeutic Use
- Acronyms TRUE-AHF
- Sponsors Cardiorentis
- 21 May 2021 This trial has been discontinued in Germany, as per European Clinical Trials Database record.
- 12 Apr 2017 Primary endpoint (Cardiovascular death rate) has not been met, according to the results published in the New England Journal of Medicine.
- 12 Apr 2017 Primary endpoint (Hierarchical clinical composite outcome 48 hr after randomization) has not been met, according to the results published in the New England Journal of Medicine.